Inhalon
Katherine Gibb has a diverse work experience in various industries. Katherine began their career at GT Independence in 2018, where they served as a Certified Nursing Assistant from April 2018 to March 2020. Following that, they worked as a Paraprofessional from March 2020 to April 2021.
In 2021, Katherine joined Mucommune, where they started as a Laboratory Assistant in October 2021 and transitioned to the role of Laboratory Manager in September 2022.
Most recently, they joined Inhalon Biopharma in 2022. At Inhalon Biopharma, Katherine has taken on the role of Quality Assurance Quality Control.
Katherine Gibb began their education in 2014 at Durham Technical Community College. Katherine pursued a general education field of study at this institution until 2015. From 2016 to 2020, they attended the University of North Carolina at Charlotte, where they obtained a Bachelor's degree in Computer Science. Katherine also holds additional certifications, including MATLAB Onramp from MathWorks obtained in July 2022, Technical Support Fundamentals from Coursera obtained in July 2021, CPR Certification from the American Heart Association | American Stroke Association obtained in May 2017, and a Certified Nursing Assistant certification from NNAAP obtained in August 2017.
This person is not in the org chart
Inhalon
Inhalon Biopharma is developing an inhaled immunotherapy platform for treating acute respiratory infections (ARI), such as syncytial virus (RSV), influenza, metapneumovirus (MPV), parainfluenza virus (PIV), adenovirus, severe acute respiratory syndrome (SARS) and middle east respiratory syndrome (MERS). Today there are no approved treatments for a wide range of ARIs that can lead to hospitalization, long-term health complications, and sometimes death.